Evaluating the oncogenic risk of residual DNA in vaccines: the potential role of transgenic mice.
There is a general consensus that residual DNA from immortalised cells is very unlikely to pose a safety risk for biotechnology products but there is little experimental data to support this contention. Transgenic mice primed with one or more oncogenes or tumour suppressor deletions offer a potentially sensitive and quantitative method for determining the presence of oncogenic DNA. Separate lines of mice transgenic for myc and Cbfa1 may provide a means of detecting oncogenic DNA containing genes belonging to different complementation groups.